Clinical stage biotech company Cocrystal Pharma Inc (NASDAQ:COCP) has emerged as one of the notable gainers over the course of the past month, having gained 14% during the period.
Yesterday, the Cocrystal stock came into sharp focus after the company announced that its COVID 19 protease inhibiting product CDI 45205 is active against the virus and also against two well known variants. The antiviral activity of the product was evaluated by an independent laboratory. It should be noted that new variants of the COVID 19 virus have wreaked havoc in many nations.
The interim Chief Executive Officer and President of the company Sam Lee spoke about the latest findings. Lee said that the company is considerably encouraged by the latest findings and went on to state that Cocrystal is going to continue with testing for antiviral activity against other variants of the virus as well. Investors could consider adding the Cocrystal stock to their watch lists at this point.
|CCI20||210.1682||OverBought||Chaikin Money Flow||0.1332||Buy|
|MACD||0.0051||Buy||Money Flow Index||80.3334||OverBought|
|STOCH (14,3)||85.2941||OverBought||STOCH RSI||1.0000||OverBought|